{"id":2934,"date":"2026-09-04T20:06:00","date_gmt":"2026-09-05T00:06:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2934"},"modified":"2026-09-05T12:07:46","modified_gmt":"2026-09-05T16:07:46","slug":"arlo-cel-phase-i-data-in-refractory-myeloma","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2934","title":{"rendered":"Arlo-cel Phase I Data in Refractory Myeloma"},"content":{"rendered":"

Online-First<\/strong> June 2, 2026 · Issue Date<\/strong> September 3, 2026 · Discovery<\/strong> September 4, 2026 · Status<\/strong> Publication catch-up · Importance<\/strong> 5\/5 · Direction<\/strong> Positive<\/p>\n

\"Arlo-cel<\/p>\n

Summary<\/h4>\n

Peer-reviewed Phase I results for arlocabtagene autoleucel (arlo-cel; BMS-986393; CC-95266), an autologous GPRC5D-directed CAR-T therapy, show clinically meaningful activity in 84 heavily pretreated patients with relapsed or refractory multiple myeloma. Overall response was 87%, complete response or better was 53%, median duration of response was 18.0 months and median progression-free survival was 18.3 months. The signal is strengthened by activity after BCMA-directed therapy, but remains single-arm and includes a treatment-related cytokine-release-syndrome death at the highest dose.<\/p>\n

What Happened<\/h4>\n

The first-in-human dose-escalation and expansion study enrolled adults after at least three prior antimyeloma regimens. Patients had received a median of five prior regimens; 49% had prior BCMA-targeted treatment. Arlo-cel was infused once at 25 million to 450 million CAR-T cells after lymphodepletion. The data cutoff was August 23, 2024, so the current signal is peer-reviewed validation rather than a new clinical cutoff.<\/p>\n

Among 79 efficacy-evaluable patients, overall response was 87%; 53% achieved complete response or better and 42% achieved stringent complete response. Median response duration was 18.0 months and median PFS was 18.3 months; one-year overall survival was 90% after median follow-up of 16.1 months. The maximum tolerated dose was not reached.<\/p>\n

CRS occurred in 82% and ICANS in 10%; most events were grade 1 or 2. One treatment-related death from CRS occurred at 450 million cells. Grade 3 or 4 neutropenia, anemia and thrombocytopenia occurred in 70%, 32% and 29%, respectively. Forty percent had severe cytopenia beyond one month, although most recovered. Skin, nail or oral on-target\/off-tumor effects affected 49% overall and were grade 2 or lower.<\/p>\n

Deep Analysis<\/h4>\n

Mechanistically, GPRC5D is expressed on malignant plasma cells independently of BCMA, providing a rational route around BCMA loss or refractoriness. Activity in a cohort where approximately half had received BCMA-targeted treatment supports target-level non-redundancy. It does not establish the optimal sequence versus BCMA CAR-T, GPRC5D bispecific antibodies or other salvage regimens because the trial was uncontrolled and enrolled selected patients able to complete manufacturing and lymphodepletion.<\/p>\n

The response depth and approximately 18-month median durability compare favorably with expectations for late-line disease, but cross-trial comparisons are unreliable. Dose heterogeneity, evolving follow-up and the 2024 cutoff limit precision. Phase II and randomized Phase III studies must reproduce benefit at the selected dose, define outcomes in prior-BCMA and biologically high-risk subgroups, and characterize late neurotoxicity, persistent cytopenia, infections and second malignancies.<\/p>\n

The safety profile defines a real engineering and clinical window. Transient epithelial toxicities are consistent with GPRC5D expression in keratinized tissues; persistent neurologic episodes and one fatal high-dose CRS event argue against treating “MTD not reached” as absence of dose-limiting risk. Commercial readiness also depends on vein-to-vein time, manufacturing success at scale, inpatient resource use and reproducible product potency, none of which this academic publication fully resolves.<\/p>\n

Company and Product Background<\/h4>\n

Bristol Myers Squibb is developing arlo-cel, formerly CC-95266, as BMS-986393. The autologous product uses a human GPRC5D-specific single-chain variable fragment, CD28 transmembrane domain, 4-1BB costimulatory domain and CD3-zeta signaling domain. Patient T cells are collected, engineered ex vivo, expanded and reinfused after lymphodepletion to recognize GPRC5D-positive plasma cells.<\/p>\n

Multiple myeloma is a clonal plasma-cell malignancy arising in bone marrow. Relapse after proteasome inhibitors, immunomodulators, anti-CD38 antibodies and BCMA-directed therapy creates a growing population with resistant disease. GPRC5D is a plausible alternative antigen because its expression is independent of BCMA, but expression in skin and keratinized tissues explains clinically relevant on-target\/off-tumor effects.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Signal<\/th>\nVerified evidence<\/th>\nCurrent limit<\/th>\n<\/tr>\n
Human efficacy<\/td>\nORR 87%; CR or better 53%; median DOR 18.0 months; median PFS 18.3 months<\/td>\nSingle-arm Phase I; 79 efficacy-evaluable patients; data cutoff in 2024<\/td>\n<\/tr>\n
Post-BCMA relevance<\/td>\n49% previously received BCMA-targeted treatment; responses reported across subgroups<\/td>\nNo randomized sequencing evidence or validated predictive biomarker<\/td>\n<\/tr>\n
Acute safety<\/td>\nCRS 82%; ICANS 10%; most grade 1\/2<\/td>\nOne treatment-related grade-5 CRS event at the highest dose<\/td>\n<\/tr>\n
Marrow toxicity<\/td>\nGrade 3\/4 neutropenia 70%, anemia 32%, thrombocytopenia 29%<\/td>\n40% had severe cytopenia beyond one month; two stem-cell boosts<\/td>\n<\/tr>\n
Target biology<\/td>\nGPRC5D offers BCMA-independent plasma-cell targeting<\/td>\nSkin, nail and oral effects affected 49%; all reported grade 2 or lower<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull Case:<\/strong> arlo-cel could become a differentiated post-BCMA cellular option because it couples an independent target with deep, durable responses. Support includes activity in a BCMA-exposed population and 18-month median DOR. Against it, selection bias, dose pooling and lack of a comparator can inflate apparent differentiation.<\/p>\n

Bear Case:<\/strong> the dataset mainly confirms that GPRC5D is druggable, while benefit-risk and placement may resemble rather than surpass existing T-cell redirection. The fatal CRS event, prolonged cytopenias and tissue-specific adverse effects support caution. Against it, single-infusion durability could distinguish CAR-T from repeat-dose bispecific therapy if reproduced.<\/p>\n

InSilens Take<\/h4>\n

This is a high-importance, positive clinical-publication signal: arlo-cel provides the most substantial peer-reviewed validation in this scan for a BCMA-independent CAR-T strategy in late-line myeloma. The data justify late-stage testing, not a claim of therapeutic superiority or approval readiness. The decisive questions are randomized durability, post-BCMA subgroup performance and whether the selected dose reduces neurologic, marrow and on-target\/off-tumor liabilities without sacrificing depth of response.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — substantial peer-reviewed human validation of a late-stage alternative-antigen CAR-T strategy in myeloma<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — deep responses and meaningful durability outweigh, but do not erase, serious safety and design limitations<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — primary peer-reviewed article and registered trial are concordant<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — comparative value, selected-dose safety and real-world manufacturability remain unresolved<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Peer-reviewed Phase I results for arlocabtagene autoleucel (arlo-cel; BMS-986393; CC-95266), an autologous GPRC5D-directed CAR-T therapy, show clinically meaningful activity in 84 heavily pretreated patients with relapsed or refractory multiple myeloma. Overall response was 87%,…<\/p>\n","protected":false},"author":1,"featured_media":2935,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[581,557,101,583,582,30],"class_list":["post-2934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-arlo-cel","tag-bcma","tag-bristol-myers-squibb","tag-car-t","tag-gprc5d","tag-multiple-myeloma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2934"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2934\/revisions"}],"predecessor-version":[{"id":2939,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2934\/revisions\/2939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2935"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}